BSEM | Ticker Profile - Titan Protect

BSEM

BioStem Technologies, Inc.

Healthcare · Biotechnology · OID

$3.90

Data: 2026-05-14

✗ ETHICAL FAIL

WEAK MOAT

HIGH

Data Confidence: 100.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$85M

Total market value of the company

Trailing P/E

5.77

Very cheap relative to earnings

Forward P/E

17.52

Based on estimated future earnings — lower means cheaper

Rev Growth

-90.2%

Year-over-year revenue change

Profit Margin

-13.9%

How much profit the company keeps from each dollar of revenue

ROE

-16.5%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$9.00

+131% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 1 analysts covering this stock

About BioStem Technologies, Inc.

BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje AC, a thicker structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje OPTIC, a structural tissue allograft used as a protective covering during the repair of ocular surfaces; American Amnion AC, a human connective tissue matrix for homologous use; and American Amnion, a human connective tissue matrix for homologous use. The company was formerly known as Caribbean International Holdings Inc. and changed its name to BioStem Technologies, Inc. in August 2014. BioStem Technologies, Inc. was incorporated in 2006 and is based in Fort Lauderdale, Florida.

https://biostemtechnologies.com

Country: United States Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

3.9% PASS

Debt must be below 33% of total assets

Cash Ratio

34.6% FAIL

Interest-bearing cash below 33% of assets

Receivables

0.0% PASS

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Valuation

Fair Value Est.

$4.35

What our model estimates this business is worth per share

Margin of Safety

10.4%

Slight discount to fair value

Rating

AVOID

Overall assessment combining ethics, valuation, and quality

Percentile

6.5th

Ranks in the top 94% of our 13,571 screened universe

Ethical Score

10.0

Valuation Score

61.0

Quality Score

15.0

Combined

N/A

Trading at $5, 17% above fair value of $4. Fails ethical screen (Cash ratio). Ranks better than 4% of screened stocks.

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKDOWN

Price trending down — defensive positioning

Sharpe Ratio

0.238

Positive but modest risk-adjusted returns

Kelly Fraction

0.0129

Marginal edge — very small allocation suggested

Calmar Ratio

-0.329

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-28.5%

Historical annualised return based on price data

Max Drawdown

-86.7%

Largest peak-to-trough decline — the worst it has been

HMM State

CRISIS

Elevated risk detected — extreme caution warranted

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.20

Very low correlation to market moves

52W High

$14.52

73% below the year high

52W Low

$3.09

26% above the year low

Avg Volume

59,366

Average daily shares traded — higher means easier to buy and sell

Short Ratio

N/A

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

0.0%

Annual dividend as a percentage of the share price

EPS (TTM)

$0.88

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

0.09

Conservative use of debt — low financial risk

Current Ratio

4.12

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

3.66

Like current ratio but excludes inventory — stricter test

Gross Margin

93.6%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-74.4%

Profit from core operations before interest and tax

Free Cash Flow

N/A

Negative — the business is spending more than it generates

Revenue (TTM)

$47M

Total revenue over the last 12 months

Net Income

$-6,580,912

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$9.00

Target Median

$9.00

Target Low

$9.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-14

Before you go